REG - GENinCode PLC - Director Appointment

GenincodeAnnouncement

06/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220406:nRSF3857Ha&default-theme=true

RNS Number : 3857H  GENinCode PLC  06 April 2022

 

GENinCode Plc

("GENinCode" or the "Company")

 

Director appointment

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces the appointment to the
Board of Felix Frueh, PhD ("Felix") as a Non-Executive Director.

 

Felix is a senior life sciences executive with in-depth expertise in
corporate, regulatory, and commercialisation strategies, with a particular
focus on precision medicine. He has over 25 years of experience setting
scientific and corporate strategy in precision medicine, and has founded
several start-ups in the diagnostics and pharmaceutical sectors. He has worked
in the regulatory space for 18 years, including five years working with the
FDA.

 

In addition to his FDA career, Felix oversaw the creation and operations of
the world's largest next-generation, Clinical Laboratory Improvement
Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the
Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as
President of Medco Research Institute, Research Director for Pharmacogenetics
of Transgenomic, and Assistant Director of Protogene Laboratories. He is
Founder and Executive Partner of Opus Three, Co-Founder and Partner of
Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva
Therapeutics. He also co-founded and formerly served as the Chief Executive
Officer of Intellos Health.

 

Felix received his PhD in biochemistry from the University
of Basel in Switzerland and completed postdoctoral fellowships at the
University of Basel and Stanford University. He has served as a consultant,
strategic advisor, and Board member to numerous diagnostic, pharmaceutical,
and other healthcare companies. He is the author of more than 100
peer-reviewed articles, book chapters, white papers, market analyses,
strategies, and business plans.

 

Matthew Walls, CEO of GENinCode Plc commented: "We are delighted that Felix is
joining as a Non-Executive Director. Felix can offer us invaluable insights
into the FDA as we start to look towards commericalisation in the US later
this year, and his many years of experience in key roles in the industry will
be a huge benefit to us. His depth of knowledge in precision medicine and
regulatory affairs is second-to-none and we are looking forward to
capitalising on his expertise."

 

Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented: "Our goal is
to improve the current standard of care in cardiovascular disease worldwide
through our unique portfolio of products, and Felix has the experience and
expertise to help us achieve this. I am looking forward to working with him,
as is the entire GENincode team, and welcome him to the Board."

 

Felix Frueh, PhD added: "I am thrilled to have been asked to join the Board of
GENinCode at this critical stage. I have spent most of my career in the
precision medicine space and feel I can add real value to the team."

 

Regulatory disclosures

 The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Felix Wilhelm
Frueh, aged 54:

 Current Directorships    Previous Directorships
 Opus Three Partners LLC  Intellos Health LLC

 Selva Therapeutics       Enterome SA

 Bloom Science, Inc.      Ariana Pharmaceuticals SA

 AZCERT

 

As of the date of this announcement, Felix Frueh holds no ordinary shares in
the capital of the Company. Save as disclosed above there are no additional
disclosures to be made in accordance with Rule 17 or Schedule Two paragraph
(g) of the AIM Rules for Companies.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

 GENinCode Plc                              www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)       Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                        Tel: 020 7933 8780 or
 Anna Dunphy / Paul McManus / Louis Ashe-Jepson                               genincode@walbrookpr.com

 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, in the United States through
GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an
estimated 17.9 million lives each year. CVD is a group of disorders of the
heart and blood vessels and include coronary heart disease, cerebrovascular
disease, rheumatic heart disease and other conditions. More than four out of
five CVD deaths are due to heart attacks and strokes, and one third of these
deaths occur prematurely in people under 70 years of age.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Cessation of tobacco use, reduction of salt in the diet, eating more fruit and
vegetables, regular physical activity and avoiding harmful use of alcohol have
been shown to reduce the risk of cardiovascular disease. Health policies that
create conducive environments for making healthy choices affordable and
available are essential for motivating people to adopt and sustain healthy
behaviours.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas and is the single biggest area where the
NHS can save lives over the next 10 years. CVD is largely preventable, through
lifestyle changes and a combination of public health and NHS action on smoking
and tobacco addiction, obesity, tackling alcohol misuse and food
reformulation.

 

Genetic risk assessment can help early detection and treatment of CVD to help
patients live longer, healthier lives. Many people are still living with
undetected, high-risk conditions such as high blood pressure, raised
cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to
identify and diagnose people routinely knowing their 'ABC' (testing and
monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year
plan.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASSMFMIEESEDL